A Double Blind Crossover Trial of Levetiracetam (Keppra®) and Placebo in the Treatment of Restless Legs Syndrome (RLS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00247364|
Recruitment Status : Completed
First Posted : November 1, 2005
Last Update Posted : November 1, 2005
|Condition or disease||Intervention/treatment||Phase|
|Restless Legs Syndrome||Drug: Levetiracetam (Keppra)||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||20 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||A Double Blind Crossover Trial of Levetiracetam (Keppra®) and Placebo in the Treatment of Restless Legs Syndrome (RLS)|
|Study Start Date :||November 2003|
|Study Completion Date :||October 2005|
- 1:To investigate the efficacy of levetiracetam when used to treat RLS.
- 2:To assess tolerability and adverse event rates.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00247364
|United States, Massachusetts|
|Sleep Health Centers|
|Newton, Massachusetts, United States, 02459|
|Principal Investigator:||John W Winkelman, MD, PhD||Sleep Health Centers, Brigham and Women's Hosptial|